Article info

Download PDFPDF
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus

Authors

  • Katerina Chatzidionysiou 1st Department of Propaedeutic and Internal Medicine, Joint Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece PubMed articlesGoogle scholar articles
  • Evangelia Samoli Department of Hygiene, Epidemiology, and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece PubMed articlesGoogle scholar articles
  • Petros P Sfikakis 1st Department of Propaedeutic and Internal Medicine, Joint Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece PubMed articlesGoogle scholar articles
  • Maria G Tektonidou 1st Department of Propaedeutic and Internal Medicine, Joint Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Maria G Tektonidou, Associate Professor in Rheumatology, Head of Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, ‘Laiko’ Hospital, 17 Agiou Thoma str, 11527 Athens, Greece; mtektonidou{at}gmail.com
View Full Text

Citation

Chatzidionysiou K, Samoli E, Sfikakis PP, et al
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus

Publication history

  • Received September 27, 2019
  • Revised October 15, 2019
  • Accepted October 30, 2019
  • First published November 11, 2019.
Online issue publication 
January 27, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.